French recommendations on strategies for preventing and treating osteoporosis induced by adjuvant breast cancer therapies

Standard adjuvant therapies for breast cancer such as chemotherapy or aromatase inhibitor and LH-RH agonist hormone therapy are associated with significant survival gains but also induce bone loss by aggravating the estrogen deprivation. The bone loss may be substantial, notably during early treatment, and occurs regardless of the baseline bone mineral density values. The objective of developing these recommendations was to achieve a practical consensus among various scientific societies, based on literature review, about osteoporosis prevention and treatment in these patients. The following scientific societies contributed to the work: Societe Francaise de Rhumatologie (SFR), Groupe de Recherche et d'Information sur les Osteoporoses (GRIO), Groupe Europeen d'Etudes des Metastases Osseuses (GEMO), Association Francophone pour les Soins Oncologiques de Support (AFSOS), Societe Francaise de Senologie et de Pathologie Mammaire (SFSPM), Societe Francaise de Radiotherapie Oncologique (SFRO). Drug prescription and reimbursement modalities in France were taken into account. These recommendations apply to postmenopausal women taking systemic chemotherapy and/or aromatase inhibitor therapy, non-postmenopausal women taking LH-RH agonist therapy, and non-postmenopausal women with persistent amenorrhea 1 year after chemotherapy completion. All women in these three categories should undergo an evaluation of bone health and receive interventions to combat risk factors for bone loss. Patients with a history of severe osteoporotic fracture and/or a T-score value <-2.5 should receive osteoporosis drug therapy. The FRAX (R) score should be used to guide treatment decisions in patients whose T-score is between -1 and -2.5. General osteoporosis prevention measures should be applied in patients without criteria for osteoporosis drug therapy, who should undergo bone mineral density measurements 18-24 months later if the baseline T-score is < -1 and 3-5 years later if the baseline T-score is > -1. The anti-tumor effect of bisphosphonates and denosumab was not considered when establishing these recommendations. (C) 2019 Published by Elsevier Masson SAS on behalf of Societe francaise de rhumatologie.